Mostafa A Borahay1, Xiao Fang2, Jacques G Baillargeon2, Gokhan S Kilic3, Darren F Boehning4, Yong-Fang Kuo2. 1. Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX; Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX. Electronic address: maboraha@utmb.edu. 2. Department of Preventive Medicine and Community Health, University of Texas Medical Branch at Galveston, Galveston, TX. 3. Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX. 4. Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX.
Abstract
BACKGROUND: Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. OBJECTIVE: We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. STUDY DESIGN: We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95% confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. RESULTS: Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95% confidence interval, 0.83-0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95% confidence interval, 0.84-0.91), anemia (odds ratio, 0.84; 95% confidence interval, 0.79-0.88), or pelvic pain (odds ratio, 0.85; 95% confidence interval, 0.81-0.91) and of undergoing myomectomy (odds ratio, 0.76; 95% confidence interval, 0.66-0.87) compared to nonusers. CONCLUSION: The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted. Copyright Â
BACKGROUND: Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. OBJECTIVE: We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. STUDY DESIGN: We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95% confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. RESULTS: Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95% confidence interval, 0.83-0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95% confidence interval, 0.84-0.91), anemia (odds ratio, 0.84; 95% confidence interval, 0.79-0.88), or pelvic pain (odds ratio, 0.85; 95% confidence interval, 0.81-0.91) and of undergoing myomectomy (odds ratio, 0.76; 95% confidence interval, 0.66-0.87) compared to nonusers. CONCLUSION: The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted. Copyright Â
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Najat Ziyadeh; Daniel Fife; Alexander M Walker; Gregg S Wilkinson; John D Seeger Journal: Adv Skin Wound Care Date: 2011-01 Impact factor: 2.347
Authors: Luca Simeone; Gaetano Mangiapia; Carlo Irace; Antonio Di Pascale; Alfredo Colonna; Ornella Ortona; Lorenzo De Napoli; Daniela Montesarchio; Luigi Paduano Journal: Mol Biosyst Date: 2011-09-07
Authors: A Thibault; D Samid; A C Tompkins; W D Figg; M R Cooper; R J Hohl; J Trepel; B Liang; N Patronas; D J Venzon; E Reed; C E Myers Journal: Clin Cancer Res Date: 1996-03 Impact factor: 12.531
Authors: S Kato; S Smalley; A Sadarangani; K Chen-Lin; B Oliva; J Brañes; J Carvajal; R Gejman; G I Owen; M Cuello Journal: J Cell Mol Med Date: 2009-05-11 Impact factor: 5.310
Authors: Sadia Afrin; Malak El Sabeh; Md Soriful Islam; Mariko Miyashita-Ishiwata; Minnie Malik; William H Catherino; Askar M Akimzhanov; Darren Boehning; Qiwei Yang; Ayman Al-Hendy; James H Segars; Mostafa A Borahay Journal: Pharmacol Res Date: 2021-08-28 Impact factor: 10.334
Authors: Shannon K Laughlin-Tommaso; Erika L Fuchs; Melissa F Wellons; Cora E Lewis; Ronit Calderon-Margalit; Elizabeth A Stewart; Pamela J Schreiner Journal: J Womens Health (Larchmt) Date: 2018-11-09 Impact factor: 3.017